DECN Provides First Looks At Its GenViro(TM) Corona Virus Screening Kit & First Year Product Forecast of 420 Million Kits, with Sales Beginning Late 3Q 2020
Press Release 03/11/2020
Initial Sales of GenVirotm Covid19 to be to Big Box Pharmacies, Group Practices, Long Term Care Facilities and Stand-alone Clinics; Average Wholesale Price of the Kit Expected to be @ $6.95
LOS ANGELES, CA / ACCESSWIRE / March 11, 2020 / Decision Diagnostics Corp. (OTC PINK
ECN) is an 18-year old, diabetes-focused bio-technology development firm, manufacturer, quality plan administrator, FDA registered medical device customer support organization, and exclusive worldwide sales and regulatory process agent for the GenUltimate! ("Sunshine"
diabetes test strip, its GenAccord! systems for the uninsured and under-insured, its GenChoice! ("Ladybug" test strip now in the later stages of FDA 510(k) prosecution, and its GenUltimate Precis products manufactured for International markets.
Today, in the third discussion of our break-through test for the coronavirus (COVID19), we present the Coronavirus test kit and the Phase 1 unit forecast. The introduction of our new screening methodology for the Coronavirus (Covid19) will provide a timely, simple to use and cost effective solution for the screening of the frightening COVID19 virus. First uses of our kits will be in pharmacies, doctor's offices, clinics and urgent care centers, and long term care facilities. We anticipate the sale of 420,000,000 kits in the first full year of commercial sale. The company has retained FDA counsel who is in the process of securing expected emergency waiver for diagnostics and diagnostic devices.
https://www.otcmarkets.com/stock/DECN/news/DE...?id=256208
Press Release 03/11/2020
Initial Sales of GenVirotm Covid19 to be to Big Box Pharmacies, Group Practices, Long Term Care Facilities and Stand-alone Clinics; Average Wholesale Price of the Kit Expected to be @ $6.95
LOS ANGELES, CA / ACCESSWIRE / March 11, 2020 / Decision Diagnostics Corp. (OTC PINK
ECN) is an 18-year old, diabetes-focused bio-technology development firm, manufacturer, quality plan administrator, FDA registered medical device customer support organization, and exclusive worldwide sales and regulatory process agent for the GenUltimate! ("Sunshine" diabetes test strip, its GenAccord! systems for the uninsured and under-insured, its GenChoice! ("Ladybug" test strip now in the later stages of FDA 510(k) prosecution, and its GenUltimate Precis products manufactured for International markets. Today, in the third discussion of our break-through test for the coronavirus (COVID19), we present the Coronavirus test kit and the Phase 1 unit forecast. The introduction of our new screening methodology for the Coronavirus (Covid19) will provide a timely, simple to use and cost effective solution for the screening of the frightening COVID19 virus. First uses of our kits will be in pharmacies, doctor's offices, clinics and urgent care centers, and long term care facilities. We anticipate the sale of 420,000,000 kits in the first full year of commercial sale. The company has retained FDA counsel who is in the process of securing expected emergency waiver for diagnostics and diagnostic devices.
https://www.otcmarkets.com/stock/DECN/news/DE...?id=256208
2
